Personalized anti-tumor vaccine enhances immunotherapy for liver cancer

NewsGuard 100/100 Score

Adding a personalized anti-tumor vaccine to standard immunotherapy is safe and about twice as likely to shrink cancer as standard immunotherapy alone for patients with hepatocellular carcinoma, the most common type of liver cancer, according to a clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center and its Convergence Institute. 

The study will be published April 7 in Nature Medicine, with findings also presented at 1:30 p.m. PT at the annual meeting of the American Association for Cancer Research. 

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. Fewer than one in 10 patients survive five years post-diagnosis. Existing immune therapies such as PD-1 immune checkpoint inhibitors, aimed at releasing restraints cancer cells place on the immune system, have limited effects. 

A preliminary clinical trial led by Kimmel Cancer Center investigators shows that adding a personalized anti-tumor vaccine to PD-1 inhibitor therapy may improve patient outcomes. The study enrolled 36 patients with HCC. All patients received the PD-1 inhibitor pembrolizumab in combination with a personalized anti-tumor vaccine. The most common adverse effect associated with the vaccine was mild injection site reactions. There were no serious adverse events. Nearly one-third of the patients treated with the combination therapy saw their tumors shrink-;about twice as many patients as seen in studies of anti-PD-1 therapy alone in HCC. About 8% had a complete response with no evidence of tumor left after the combination treatment. 

The study provides evidence that a personalized cancer vaccine can enhance clinical responses to anti-PD-1 therapy. A larger randomized clinical trial will be needed to confirm this finding, but the results are incredibly exciting." 

Mark Yarchoan, M.D., lead author, associate professor of oncology at the Johns Hopkins University School of Medicine

Decades of experience and research with cancer vaccines from study co-author Elizabeth Jaffee, M.D., deputy director of the Kimmel Cancer Center and the Dana and Albert "Cubby" Broccoli Professor of Oncology, and other visionary Johns Hopkins scientists have made the successful trial possible. Jaffee and her colleagues saw the potential of cancer vaccines early on and worked to overcome challenges to their development. 

"We are at an exciting time in new therapy development. Personalized vaccines are the next generation of vaccines that are showing promise in treating difficult cancers when given with immune checkpoint therapy. Our Cancer Convergence Institute provided technology and computational tools to make the analyses possible," says Jaffee, who is also director of the Convergence Institute. 

To make personalized cancer vaccines, scientists take tumor biopsy cells to identify cancer-associated genetic mutations in the tumor. The scientists use a computer algorithm to determine which of the mutated genes produce proteins the immune system can recognize. Then, scientists manufacture a personalized vaccine containing the DNA for the selected mutated genes. Each vaccine may include up to 40 genes. The vaccine helps the immune system recognize the abnormal proteins encoded in the selected genes and destroy cells producing them. 

Combining the personalized vaccine with the PD-1 inhibitor provides a one-two punch to the tumor. The PD-1 inhibitor helps revive immune cells, called T-cells, in the tumor that have become exhausted and unable to destroy the tumor cells. The personalized vaccine calls in the cavalry, helping recruit a fresh set of T-cells that target the specific mutant proteins in the tumor. 

When the research team evaluated tumor biopsy samples taken from the study participants after they received the vaccine, they found evidence that T-cells were created in response to the vaccine that travelled to the tumor and attacked tumor cells. They also found that patients who received vaccines targeting the greatest number of mutant proteins had the best responses. This finding may help scientists create even more effective personalized cancer vaccines. 

Recent studies have demonstrated that personalized cancer treatments may prevent recurrence in patients who had surgery to remove skin or pancreas cancer tumors. The new study adds to our understanding, suggesting that personalized cancer vaccines may also help shrink or eliminate established tumors, and is therefore an approach that could be helpful across many types of cancers beyond liver cancer. 

"The role of personalized cancer vaccines is expanding," Yarchoan says. 

Additional study co-authors were Daniel H. Shu, Elana J. Fertig and Luciane T. Kagohara of Johns Hopkins. Other researchers contributing to the work were from the New Zealand Liver Transplant Unit at the University of Auckland in New Zealand; the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai in New York; Personalis Inc. in Fremont, California; Confluence Stat in Cooper City, Florida; University of Central Florida College of Medicine in Orlando; and the Vaccine and Immunotherapy Center at The Wistar Institute and Geneos Therapeutics in Philadelphia where the vaccine platform was developed. 

The trial was sponsored by Geneos Therapeutics. 

Source:
Journal reference:

Yarchoan, M., et al. (2024). Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nature Medicine. doi.org/10.1038/s41591-024-02894-y.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers decipher how immune cells spot cancer's turbocharged metabolism